PATENT CLAIM ANALYSIS

Application Number: 15896779
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-09
Patent Classification: ["514", "210000"]

Abstract:
The present invention discloses compounds according to Formula I: Wherein R 1 , R 2 , R 3a , R 3b , and Cy are as defined herein. The present invention relates to compounds inhibiting ADAMTS, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory conditions, and/or diseases involving degradation of cartilage and/or disruption of cartilage homeostasis by administering a compound of the invention.

Claim (Index 1):
A compound according to Formula I: wherein R 1  is:\n H, \n C 1-4  alkyl optionally substituted with one or more independently selected R 4  groups, \n C 3-7  monocyclic cycloalkyl optionally substituted with one or more independently selected R 4  groups, \n 4-7 membered monocyclic heterocycloalkyl comprising 1 to 2 heteroatoms independently selected from N, O, or S, optionally substituted with one or more independently selected C 1-4  alkyl, \u2014C(\u2550O)C 1-4  alkyl, or \u2014C(\u2550O)OC 1-4  alkyl, \n phenyl optionally substituted with one or more independently selected R 5  groups, \n phenyl fused to a 5-6 membered monocyclic heterocycloalkyl comprising 1, 2 or 3 heteroatoms independently selected from N, O, or S, which heterocycloalkyl is optionally substituted with one or more \u2550O, \n 5-6 membered monocyclic heteroaryl comprising 1 or 2 heteroatoms independently selected from N, O, or S, optionally substituted with one or more independently selected R 5  groups; \n R 2  is independently selected from:\n H, \n OH, \n C 1-4  alkoxy, or \n C 1-4  alkyl optionally substituted with one\n OH, \n \u2014CN, \n C 1-4  alkoxy optionally substituted with one phenyl, or \n 5-6 membered monocyclic heteroaryl comprising 1 or 2 heteroatoms independently selected from N, O, or S, optionally substituted with one or more independently selected C 1-4  alkyl; \n \n each R 3a , and R 3b  is independently selected from:\n H, or \n C 1-4  alkyl; \n Cy is\n 6-10 membered monocyclic or fused bicyclic aryl optionally substituted with one or more independently selected R 6  groups, \n 5-10 membered monocyclic or fused bicyclic heteroaryl comprising 1, 2 or 3 heteroatoms independently selected from N, O, or S, optionally substituted with one or more independently selected R 6  groups; \n R 4  is\n halo, \n OH, \n \u2014CN, \n C 1-4  alkyl, \n C 1-4  alkoxy optionally substituted with C 1-4  alkoxy, or phenyl, \n C 1-4  thioalkoxy, \n 4-7-membered monocyclic heterocycloalkyl comprising one or more heteroatoms independently selected from N, S, or O, optionally substituted with one or more halo, \n or \n \u2014C(O)OC 1-4  alkyl, \n phenyl, \n S\u2014(\u2550O) 2 C 1-4  alkyl \n C\u2014(\u2550O)OR 7a  \n \u2014C(\u2550O)NR 7b R 7c  \n \u2014NHC(\u2550O)OR 7d  \n \u2014NHC(\u2550O)R 7e , or \n \u2014NR 8a R 8b ; \n each R 5  is\n halo, \n OH, \n \u2014CN, \n C 1-4  alkyl optionally substituted with one or more independently selected halo, \u2014NR 9a R 9b , or \u2014C(\u2550O)NR 9c R 9d , \n C 1-4  alkoxy optionally substituted with \u2014NR 9e R 9f , or \n \u2014S(\u2550O) 2 C 1-4  alkyl; \n each R 6  is\n halo, \n \u2014CN, \n \u2014NO 2 , \n \u2014CH 3 , \n 5-10 membered monocyclic or fused bicyclic heteroaryl comprising 1, 2 or 3 heteroatoms independently selected from N, O, or S, optionally substituted with one or more independently selected halo, C 1-4  alkyl, or C 1-4  alkoxy, or \n \u2014NR 9g R 9h ; \n each R 7a , R 7b , R 7c , R 7d , or R 7e , is\n \u2014H, or \n C 1-4  alkyl optionally substituted with OH, or C 1-4  alkoxy; \n each R 8a , or R 8b  is independently selected from\n H, or \n C 1-4  alkyl optionally substituted with OH, C 1-4  alkoxy, or phenyl; \n each R 9a , R 9b , R 9c , R 9d , R 9e , R 9f , R 9g , and R 9h  is independently selected from H, or C 1-4  alkyl; or a pharmaceutically acceptable salt, or a solvate, or a pharmaceutically acceptable salt of a solvate thereof; or a biologically active metabolite thereof; provided that:\n R 1  and R 2  are not simultaneously H, and \n when R 1  is Me, and R 2  is H, then Cy is not \n or a pharmaceutically acceptable salt, or a solvate, or the salt of the solvate thereof.

Metadata:
- Claim Count in Document: 75.0
- Percentile: 88.0
- Lexical Diversity: 1.62264
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15538393', '16308380', '14205885', '12554611', '11958503']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7415705296280921
- 35 USC 102 Novelty (BERT): 0.6300664763559777
- Combined Prediction Score: 0.7304201243008808
- Mean Citation Score: 396.542608
- Max Citation Score: 556.40967
- Similarity Product: 554.2428276467085

Labels:
- Claim Label 101: 0
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test